AwardedBelgiumGoods
Rituximab et Trastuzumab
- Published
- Published 18 December 2024
- Deadline
- Closed 28 January 2025
Overview
Le marché concerne les fournitures de la spécialité pharmaceutique contenant le principe actif « Rituximab » en solution à diluer pour perfusion par voie intraveineuse (dosage : 500mg).
Le marché concerne également les fournitures de la spécialité pharmaceutique contenant le principe actif « Trastuzumab » en solution à diluer pour perfusion par voie intraveineuse (dosage : 150mg et 420mg).
Le marché est divisé en lots comme suit :
- Lot 1 « Rituximab par voie intraveineuse » ;
- Lot 2 « Trastuzumab par voie intraveineuse ».
Key details
- Country
- Belgium
- Status
- Awarded
- Category
- Goods
- Procedure
- Open
- Published
- 18 December 2024
- Deadline
- Closed
Medical equipments, pharmaceuticals and personal care products
Award outcome
- Awarded value
- €905,818
- Award date
- 28 February 2025
- Contract period
- — → 7 February 2029
- Celltrion Healthcare Netherlands B.V.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
6 March 2025
Contract Notice
16 January 2025
Contract Notice
18 December 2024
Contracting authority
Cliniques universitaires Saint Luc
Procuring entityBruxelles, Belgium
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.